ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH

Rosen Law Firm has filed class action lawsuits against Park Ha Biological Technology Co., Ltd. (PHH, BYAH) for securities fraud involving false statements and undisclosed fraudulent stock promotion schemes during December 2024-July 2025. A separate lawsuit targets GRAIL, Inc. (GRAL) with an August 4, 2026 deadline for investors to secure counsel. Both cases allege material misstatements and failure to disclose adverse facts affecting stock prices.

08/01/2026, 2:58 PM • GlobeNewswire

Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?

Grail's stock has declined from a record high of $116.06 to under $70 following a failed NHS England trial for its Galleri blood cancer test. However, the company continues generating revenue ($147M in 2025) through direct-to-consumer sales and is expected to grow to $281M by 2028. Despite the setback, analysts recommend holding the stock as an FDA approval could significantly boost growth prospects.

08/01/2026, 1:08 PM • The Motley Fool

GRAL DEADLINE TUESDAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL

Rosen Law Firm reminds GRAIL, Inc. investors who purchased stock between May 13, 2025 and February 19, 2026 of the August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided misleading statements about its NHS-Galleri trial results, concealing that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers.

08/01/2026, 11:33 AM • GlobeNewswire

המועד האחרון לתביעה הייצוגית נגד GRAL ביום שלישי: רוזן, יועץ למשקיעים מיומן, מעודד את משקיעי GRAIL, Inc. עם הפסדים של מעל 100,000$ להשיג ייצוג משפטי לפני המועד האחרון החשוב ב-4 באוגוסט בתביעה ייצוגית בניירות ערך – GRAL

Rosen Law Firm reminds investors in GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025 and February 19, 2026 of the August 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made misleading statements about the NHS-Galleri trial results and concealed material negative facts about the trial's ability to demonstrate cancer reduction in stages III-IV, causing investor losses.

08/01/2026, 11:33 AM • GlobeNewswire

HELE DEADLINE: The Gross Law Firm Reminds Helen of Troy Limited Investors of Upcoming Securities Class Action Deadline

The Gross Law Firm has announced securities class action lawsuits against Helen of Troy Limited (HELE) and other companies for allegedly making false and misleading statements. HELE is accused of misrepresenting the expected savings and effectiveness of Project Pegasus. The deadline for shareholders to register as potential lead plaintiffs is August 3, 2026.

07/31/2026, 10:27 AM • GlobeNewswire

GRAL Shareholder Alert: GRAIL, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for GRAIL, Inc. (NASDAQ: GRAL) regarding a securities class action lawsuit. The lawsuit alleges that GRAIL provided misleading statements about its NHS-Galleri trial, concealing that the trial period was insufficient to demonstrate reduction in Stage III-IV cancers. On February 19, 2026, GRAIL announced the primary endpoint was not achieved, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21. The deadline for lead plaintiff registration is August 4, 2026.

07/31/2026, 10:25 AM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol

A class action lawsuit has been filed against GRAIL, Inc. alleging that the company provided materially false and misleading statements regarding its NHS Galleri trial results. The complaint claims GRAIL concealed that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. On February 19, 2026, GRAIL announced that the primary endpoint was not achieved, causing the stock price to fall significantly. Investors who purchased shares between May 13, 2025, and February 19, 2026, have until August 4, 2026, to apply as lead plaintiff.

07/29/2026, 5:47 PM • GlobeNewswire

TUESDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Grail Class Action Lawsuit - GRAL

Law firm Robbins Geller has filed class action lawsuits against GRAIL, Inc., GPGI, Inc., and Wix.com Ltd., alleging that executives made false and misleading statements to investors. GRAIL investors can seek lead plaintiff status by August 4, 2026, following a 50% stock price decline after the company failed to achieve primary endpoints in its NHS-Galleri cancer screening trial.

07/29/2026, 1:35 PM • GlobeNewswire

BTGO DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BitGo Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTGO

Rosen Law Firm is notifying investors in BitGo Holdings, Inc. (NYSE: BTGO) and GRAIL, Inc. (NASDAQ: GRAL) of ongoing securities class action lawsuits. BitGo investors who purchased shares during the IPO on January 22, 2026 or between January 22 and May 13, 2026 are urged to act before the August 7, 2026 lead plaintiff deadline. The lawsuit alleges that offering documents contained false statements regarding BitGo's risk exposure to declining digital asset prices and overstated business prospects. GRAIL investors have an August 4, 2026 deadline for the class action period covering May 13, 2025 to February 19, 2026.

07/26/2026, 10:04 PM • GlobeNewswire

GRAL 集體訴訟的最後期限：全球頂尖法律事務所 ROSEN 鼓勵 GRAIL, Inc. 投資者在對 GRAL 提出證券集體訴訟的重要的截止日期 8 月 4 日之前聘請律師

Rosen Law Firm announces a securities class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) on behalf of investors who purchased shares between May 13, 2025 and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements regarding its NHS-Galleri cancer screening trial, concealing that the three-year follow-up period was insufficient to demonstrate stage III-IV cancer reduction and withholding detailed preliminary results that may have shown unfavorable trends.

07/26/2026, 7:10 PM • GlobeNewswire

GRAL DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL

A securities class action lawsuit has been filed against GRAIL, Inc. for allegedly providing misleading statements about its NHS-Galleri cancer screening trial. The lawsuit claims defendants concealed material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is August 4, 2026.

07/26/2026, 7:10 PM • GlobeNewswire

GRAL 10-DAY DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline

Hagens Berman has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging the company misled investors about its NHS-Galleri cancer screening trial's design and efficacy. GRAIL failed to meet the trial's primary endpoint on February 19, 2026, and admitted the three-year follow-up period was insufficient. The stock collapsed 50.55% in a single trading session, erasing $2.2 billion in market capitalization. The lead plaintiff deadline is August 4, 2026.

07/25/2026, 8:26 PM • GlobeNewswire

$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law

GRAIL, Inc. faces a securities fraud class action lawsuit after its stock plummeted 50% on February 20, 2026, following the announcement that its NHS-Galleri cancer trial failed to meet its primary endpoint of reducing late-stage cancers. Investors allege the company misrepresented the trial's design and results, claiming the three-year timeframe was insufficient to achieve the stated objective. The lead plaintiff deadline is August 4, 2026.

07/24/2026, 6:36 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against GRAIL, Inc. alleging that company executives made materially false and misleading statements regarding the NHS-Galleri trial's likelihood of success. The complaint claims defendants misrepresented the trial's prospects and concealed adverse data suggesting the three-year timeframe was insufficient to achieve the primary endpoint. Investors who purchased GRAIL securities between May 13, 2025 and February 19, 2026 are eligible to join the case, with a lead plaintiff deadline of August 4, 2026.

07/23/2026, 12:00 PM • GlobeNewswire

GRAL DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL

Rosen Law Firm is soliciting investors who suffered losses in GRAIL, Inc., First Solar, Inc., and Gildan Activewear Inc. to join securities class action lawsuits. The primary case involves GRAIL, Inc., where defendants allegedly made materially false statements about their NHS-Galleri trial results and concealed adverse facts about the trial's ability to demonstrate cancer reduction outcomes. The lead plaintiff deadline is August 4, 2026.

07/20/2026, 8:30 PM • GlobeNewswire